文献速递中枢神经肿瘤放疗

ATM突变改善IDH野生型高级别胶质瘤的放射敏感性:基于下一代测序数据的回顾性分析

ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
PubMed 文献 · Radiat Oncol · 2020-07-31

该回顾性研究纳入39例未行全切术的IDH野生型高级别胶质瘤患者,接受中位总剂量60 Gy/30次放疗,通过下一代测序检测ATM突变。ATM突变率为26%(10例),ATM突变组1年野内控制率为100%,显著高于ATM野生型组的44.1%(p=0.002),但野外部控制率和总生存无差异。

要点

  • ATM突变组1年野内控制率100%,ATM野生型组44.1%(p=0.002)。
  • ATM突变与野外部控制率及总生存无显著差异(p=0.861和p=0.247)。
  • ATM突变可能作为IDH野生型高级别胶质瘤放射敏感性的生物标志物。

核心结论

  • ATM突变可能与IDH野生型高级别胶质瘤的放射敏感性增加相关,表现为优异的野内控制。

研究设计与样本

  • 回顾性分析39例未行全切术的IDH野生型高级别胶质瘤患者(弥漫性星形细胞瘤2例、间变性星形细胞瘤10例、胶质母细胞瘤27例),接受中位总剂量60 Gy/30次放疗,使用TruSight Tumor 170癌症panel进行下一代测序检测ATM突变状态。

主要发现

  • 39例样本中ATM突变检出率为26%(n=10),其中胶质母细胞瘤6例、间变性星形细胞瘤4例,大多数为错义突变(n=8,80%)。
  • 中位随访16.5个月(四分位距11.4-19.8),ATM突变组1年野内控制率为100%,ATM野生型组为44.1%(p=0.002)。
  • 两组野外部控制率无差异(p=0.861),总生存无差异(p=0.247)。

关键数值与推荐

  • 疾病进展根据RANO标准及神经学和临床发现定义。
  • ATM突变组1年野内控制率100% vs ATM野生型组44.1%(p=0.002)。
  • 野外部控制率组间比较p=0.861,总生存组间比较p=0.247。

临床怎么用

  • 对于IDH野生型高级别胶质瘤患者,ATM突变状态可能有助于预测放疗野内控制效果。
  • ATM突变有望作为生物标志物和候选治疗靶点,但需进一步研究验证。

局限性

  • 回顾性分析,样本量较小(39例)。
  • 需要进一步研究揭示ATM作为生物标志物和治疗靶点的潜在作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To identify the association between somatic ataxia-telangiectasia mutated (ATM) mutations and improved radio-sensitivity, we retrospectively reviewed next-generation sequencing data from patients diagnosed with isocitrate dehydrogenase (IDH)-wildtype high-grade glioma. METHODS: We included 39 individuals with (IDH)-wildtype high-grade glioma (diffuse astrocytoma n = 2, anaplastic astrocytoma n = 10, and glioblastoma n = 27) not subjected to gross tumor resection and undergoing radiation therapy with a median total dose of 60 Gy in 30 fractions. The mutational status of the ATM gene was obtained through next-generation sequencing using a TruSight Tumor 170 cancer panel. Disease progression was defined according to the Response Assessment in Neuro-Oncology (RANO) criteria as well as neurologic and clinical findings. RESULTS: Among the 39 samples, ATM mutations (ATM mut(+)) were detected in 26% of cases (n = 10). No significant differences were observed in the characteristics of the patients or tumors. Among the 10 patients in the ATM mut(+) group, there were 6 patients with glioblastoma and 4 patients with anaplastic astrocytoma. Most mutations were missense mutations (n = 8, 80%). With a median follow-up of 16.5 mo (interquartile range, 11.4-19.8), ATM mut(+) exhibited 1-year in-field control of 100% compared with 44.1% in the ATM mut(-) group (p = 0.002). There was no difference in the out-field control rate or overall survival between the two groups (p = 0.861 and p = 0.247, respectively). CONCLUSIONS: Our results demonstrated that ATM mutations might be involved in the increased radio-sensitivity with excellent in-field control despite the aggressive nature of IDH-wildtype high-grade glioma. Further studies are necessary to uncover the potential role of ATM as a biomarker and candidate therapeutic target in high-grade gliomas.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kim N, Kim SH, Kang SG, et al. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data. Radiat Oncol. 2020. PMID: 32736562. doi:10.1186/s13014-020-01619-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。